Gertrude Biomedical
Gertrude Biomedical is an early-stage biotechnology company dedicated to developing innovative small molecule inhibitors targeting transcription factors, particularly SOX18, to treat untreatable cancers. Their mission is to create transformational oncology therapeutics that inhibit mechanisms of cancer growth and spread, focusing on rare and orphan cancers with significant unmet needs. The company combines expertise in transcription factors, medicinal chemistry, and drug development to accelerate progress towards a brighter future for cancer sufferers.
Industries
Nr. of Employees
small (1-50)
Gertrude Biomedical
North Melbourne, Victoria, Australia, Oceania
Products
Small-molecule therapeutic program targeting transcription factor pathways
Early-stage drug discovery program focused on small molecules that inhibit transcription factor activity to modulate gene pathways driving cancer growth, with initial focus on a transcription factor implicated in vascular and lymphatic biology.
Small-molecule therapeutic program targeting transcription factor pathways
Early-stage drug discovery program focused on small molecules that inhibit transcription factor activity to modulate gene pathways driving cancer growth, with initial focus on a transcription factor implicated in vascular and lymphatic biology.
Services
Partnering for drug development and commercialisation
Engagements with investors and industry partners for licensing, co-development, and commercial strategy to advance therapeutic candidates.
Preclinical development and translational research
Preclinical candidate evaluation including disease model selection, pharmacology, formulation input and PK/ADME characterization to support lead progression.
Partnering for drug development and commercialisation
Engagements with investors and industry partners for licensing, co-development, and commercial strategy to advance therapeutic candidates.
Preclinical development and translational research
Preclinical candidate evaluation including disease model selection, pharmacology, formulation input and PK/ADME characterization to support lead progression.
Expertise Areas
- Small-molecule oncology drug discovery
- Transcription factor-targeted therapeutics
- Medicinal chemistry and lead optimisation
- Preclinical pharmacology and in vivo models
Key Technologies
- Small-molecule drug discovery
- Transcription factor targeting
- Structure-based and ligand-based drug design
- Computational chemistry and molecular modelling